CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
In This Article:
BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its recent feature in Fortune magazine.
In the article, titled “A New Hope for Dementia Treatment”, CervoMed was recognized for its pioneering work in developing neflamapimod, a potentially transformative treatment for patients suffering from dementia with Lewy bodies (DLB).
“We are honored to be featured in Fortune and to have our contributions to DLB research and recent clinical trial results acknowledged on such a prominent platform,” said John Alam, MD, Chief Executive Officer of CervoMed. “DLB affects over 1.4 million people in the U.S. and despite the high prevalence, there are no treatments approved, leaving a critical gap in effective therapeutic options. The results from our Phase 2a AscenD-LB trial indicate that our lead product neflamapimod may not only slow cognitive and motor decline but also has the potential to partially restore cognitive and motor functions in DLB patients. We believe that neflamapimod offers the potential for groundbreaking progress in the treatment of DLB, and we look forward to sharing the topline results from our Phase 2b RewinD-LB study in December 2024.”
In addition to the Fortune article, Dr. Alam was recently interviewed on the Biotech 2050 podcast, where he provides an in-depth look at the scientific and strategic advancements being made at CervoMed and shares his vision for transforming the treatment landscape for dementia.
About the RewinD-LB Phase 2b Study in Dementia with Lewy Bodies
CervoMed’s ongoing Phase 2b study, RewinD-LB, is a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod (40mg TID) in 159 patients with early-stage DLB. In early-stage DLB patients – who are estimated to comprise approximately 50% of the total diagnosed DLB patient population at any given time – the disease has not progressed to a point where the patient has significant neuronal loss in the hippocampus. Patients with advanced DLB – in whom there is significant, irreversible neuronal loss in the hippocampus and associated Alzheimer’s Disease co-pathology – as assessed by a blood biomarker (plasma ptau181), were excluded from the study. The primary endpoint in the study is change in the Clinical Dementia Rating Sum of Boxes, and secondary endpoints include the Timed Up and Go test, a cognitive test battery, and the Clinician’s Global Impression of Change. The RewinD-LB study is funded by a $21.0 million grant from the National Institutes of Health’s National Institute on Aging, which is being disbursed over the course of the study as costs are incurred. The study includes 43 sites (32 in the United States, 8 in the United Kingdom, and 3 in the Netherlands) and completed enrollment in June 2024, with topline data expected in December 2024. Patients completing the 16-week placebo-controlled study period will be able to continue in the study while receiving open label neflamapimod treatment for an additional 32 weeks. More information on the RewinD-LB study, including contact information on active clinical trial sites, is available at clinicaltrials.gov.